Updates on Rare Genetic Variants, Genetic Testing, and Gene Therapy in Individuals With Obesity

Overview

Journal Curr Obes Rep

Specialty Endocrinology

Date 2024 Jun 1

PMID 38822963

Authors

Michael V Zuccaro

Charles A LeDuc

Vidhu V Thaker

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: The goal of this paper is to aggregate information on monogenic contributions to obesity in the past five years and to provide guidance for genetic testing in clinical care.

Recent Findings: Advances in sequencing technologies, increasing awareness, access to testing, and new treatments have increased the utilization of genetics in clinical care. There is increasing recognition of the prevalence of rare genetic obesity from variants with mean allele frequency < 5% -new variants in known genes as well as identification of novel genes- causing monogenic obesity. While most of these genes are in the leptin melanocortin pathway, those in adipocytes may also contribute. Common variants may contribute either to higher lifetime tendency for weight gain or provide protection from monogenic obesity. While specific genetic mutations are rare, these segregate in individuals with early-onset severe obesity; thus, collectively genetic etiologies are not as rare. Some genetic conditions are amenable to targeted treatment. Research into the discovery of novel genetic causes as well as targeted treatment is growing over time. The utility of therapeutic strategies based on the genetic risk of obesity is an advancing frontier.

References

Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J . Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015; 17(5):405-24. PMC: 4544753. DOI: 10.1038/gim.2015.30. View

Heymsfield S, Avena N, Baier L, Brantley P, Bray G, Burnett L . Hyperphagia: current concepts and future directions proceedings of the 2nd international conference on hyperphagia. Obesity (Silver Spring). 2014; 22 Suppl 1:S1-S17. PMC: 4159941. DOI: 10.1002/oby.20646. View

Mendoza-Caamal E, Barajas-Olmos F, Mirzaeicheshmeh E, Ilizaliturri-Flores I, Aguilar-Salinas C, Gomez-Velasco D . Two novel variants in DYRK1B causative of AOMS3: expanding the clinical spectrum. Orphanet J Rare Dis. 2021; 16(1):291. PMC: 8247206. DOI: 10.1186/s13023-021-01924-z. View

Saeed S, Ning L, Badreddine A, Mirza M, Boissel M, Khanam R . Biallelic Mutations in P4HTM Cause Syndromic Obesity. Diabetes. 2023; 72(9):1228-1234. PMC: 7617486. DOI: 10.2337/db22-1017. View

Bamshad M, Le T, Watkins W, Dixon M, Kramer B, Roeder A . The spectrum of mutations in TBX3: Genotype/Phenotype relationship in ulnar-mammary syndrome. Am J Hum Genet. 1999; 64(6):1550-62. PMC: 1377898. DOI: 10.1086/302417. View

Roizen J, Danzig J, Groleau V, McCormack S, Casella A, Harrington J . Resting Energy Expenditure Is Decreased in Pseudohypoparathyroidism Type 1A. J Clin Endocrinol Metab. 2015; 101(3):880-8. PMC: 4803160. DOI: 10.1210/jc.2015-3895. View

Clement K, van den Akker E, Argente J, Bahm A, Chung W, Connors H . Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. Lancet Diabetes Endocrinol. 2020; 8(12):960-970. DOI: 10.1016/S2213-8587(20)30364-8. View

Stunkard A, Messick S . The three-factor eating questionnaire to measure dietary restraint, disinhibition and hunger. J Psychosom Res. 1985; 29(1):71-83. DOI: 10.1016/0022-3999(85)90010-8. View

Roberts K, Chaves E, Ariza A, Thaker V, Cho C, Binns H . Exploring Genetic Testing for Rare Disorders of Obesity: Experience and Perspectives of Pediatric Weight Management Providers. Child Obes. 2024; 20(7):451-458. PMC: 11535453. DOI: 10.1089/chi.2023.0125. View

10.

Nalbantoglu O, Hazan F, Acar S, Gursoy S, Ozkan B . Screening of non-syndromic early-onset child and adolescent obese patients in terms of and gene variants by next-generation sequencing. J Pediatr Endocrinol Metab. 2022; 35(8):1041-1050. DOI: 10.1515/jpem-2022-0027. View

11.

Akbari P, Gilani A, Sosina O, Kosmicki J, Khrimian L, Fang Y . Sequencing of 640,000 exomes identifies variants associated with protection from obesity. Science. 2021; 373(6550). PMC: 10275396. DOI: 10.1126/science.abf8683. View

12.

Saeed S, Janjua Q, Haseeb A, Khanam R, Durand E, Vaillant E . Rare Variant Analysis of Obesity-Associated Genes in Young Adults With Severe Obesity From a Consanguineous Population of Pakistan. Diabetes. 2022; 71(4):694-705. DOI: 10.2337/db21-0373. View

13.

Quarta C, Fisette A, Xu Y, Collden G, Legutko B, Tseng Y . Functional identity of hypothalamic melanocortin neurons depends on Tbx3. Nat Metab. 2020; 1(2):222-235. PMC: 8291379. DOI: 10.1038/s42255-018-0028-1. View

14.

Wang C, Lundh M, Fu A, Kriszt R, Huang T, Lynes M . CRISPR-engineered human brown-like adipocytes prevent diet-induced obesity and ameliorate metabolic syndrome in mice. Sci Transl Med. 2020; 12(558). PMC: 7704293. DOI: 10.1126/scitranslmed.aaz8664. View

15.

Krishna R, Gumbiner B, Stevens C, Musser B, Mallick M, Suryawanshi S . Potent and selective agonism of the melanocortin receptor 4 with MK-0493 does not induce weight loss in obese human subjects: energy intake predicts lack of weight loss efficacy. Clin Pharmacol Ther. 2009; 86(6):659-66. DOI: 10.1038/clpt.2009.167. View

16.

Iepsen E, Zhang J, Thomsen H, Hansen E, Hollensted M, Madsbad S . Patients with Obesity Caused by Melanocortin-4 Receptor Mutations Can Be Treated with a Glucagon-like Peptide-1 Receptor Agonist. Cell Metab. 2018; 28(1):23-32.e3. DOI: 10.1016/j.cmet.2018.05.008. View

17.

Welling M, de Groot C, Kleinendorst L, van der Voorn B, Burgerhart J, van der Valk E . Effects of glucagon-like peptide-1 analogue treatment in genetic obesity: A case series. Clin Obes. 2021; 11(6):e12481. PMC: 9286843. DOI: 10.1111/cob.12481. View

18.

Lutkewitte A, Singer J, Shew T, Martino M, Hall A, He M . Multiple antisense oligonucleotides targeted against monoacylglycerol acyltransferase 1 (Mogat1) improve glucose metabolism independently of Mogat1. Mol Metab. 2021; 49:101204. PMC: 8027266. DOI: 10.1016/j.molmet.2021.101204. View

19.

Kernohan K, Boycott K . The expanding diagnostic toolbox for rare genetic diseases. Nat Rev Genet. 2024; 25(6):401-415. DOI: 10.1038/s41576-023-00683-w. View

20.

Vogel P, Ding Z, Read R, DaCosta C, Hansard M, Small D . Progressive Degenerative Myopathy and Myosteatosis in ASNSD1-Deficient Mice. Vet Pathol. 2020; 57(5):723-735. DOI: 10.1177/0300985820939251. View